Key takeaways
These excerpts come from the original article. Read the full sections below for context.
- The team will usually review everyday function, comorbidity, kidney health, infection, and neurological symptoms before discussing autologous transplantation. Age provides context but should not decide the entire pathway. Temporary weakness caused by anemia, pain, or infection should also be distinguished from longstanding limitations due to serious comorbid disease. EHA–EMN 2025 myeloma guideline
- Infection susceptibility arises from the disease and its treatment. Review previous infections and vaccination history and obtain the preventive medicines appropriate to the proposed regimen. Patients do not all need the same antimicrobial program, and absence of fever is not a reason to stop prescribed prevention. Obtain a practical contact route for fever and a place for urgent local assessment. IMWG infection-prevention consensus
- China's 2025 national guidance on new anticancer medicines describes relevant myeloma medicines and use considerations. Formulations and combinations can have different scopes, including for daratumumab. The receiving team should check the current applicable documents rather than describe every overseas-approved combination as automatically available in China. National Health Commission guidance release
Quick answer
First-line treatment is the initial systemic strategy used to control active myeloma. Understanding it requires more than recognizing a regimen abbreviation. The patient should know why the combination was selected, when response will be reviewed, whether transplantation remains part of the plan, and what to do if toxicity develops. Clear arrangements during the first weeks help later treatment proceed coherently.
Full guide
First-line treatment is the initial systemic strategy used to control active myeloma. Understanding it requires more than recognizing a regimen abbreviation. The patient should know why the combination was selected, when response will be reviewed, whether transplantation remains part of the plan, and what to do if toxicity develops. Clear arrangements during the first weeks help later treatment proceed coherently.
Rapid kidney deterioration, significant hypercalcemia, infection, or symptoms suggesting spinal cord compression can require urgent management alongside anticancer treatment. Patients should not independently delay care while waiting for every appointment or specialized report. This discussion concerns people whose clinicians have established a need for treatment; MGUS and smoldering myeloma require their own assessment.
Begin with tolerance and the direction of the treatment pathway
The team will usually review everyday function, comorbidity, kidney health, infection, and neurological symptoms before discussing autologous transplantation. Age provides context but should not decide the entire pathway. Temporary weakness caused by anemia, pain, or infection should also be distinguished from longstanding limitations due to serious comorbid disease. EHA–EMN 2025 myeloma guideline
For a transplant-eligible person, induction should preserve a workable route to collection and transplantation. A transplant-ineligible person can still have an effective continuing drug strategy. Personal preference belongs in the discussion, but declining transplantation and being medically unsuitable do not necessarily describe the same trial population or drug indication.
Explain practical limits before the prescription is finalized. Frequent visits, difficulty managing a tablet schedule, or major problems with steroid-related sleeplessness can affect completion. A treatment's appropriateness depends on the evidence and on whether the patient can safely carry it out with the support available.
In eligible patients, view induction as part of the full strategy
Initial combinations commonly use a proteasome inhibitor, an immunomodulatory medicine, and a steroid, with an anti-CD38 antibody in some strategies. The exact choice reflects risk, physical condition, and applicable access requirements. Ask how long induction is expected to last, when it will be assessed, and when the collection team should become involved.
PERSEUS supports a daratumumab-containing pathway in transplant-eligible newly diagnosed patients, but its comparison involved induction, consolidation, and maintenance arrangements. It does not show that adding the same drug at any arbitrary point produces an identical benefit. Ask which parts of the trial pathway resemble your recommendation and what supports any planned differences. PERSEUS randomized trial
Collection, autologous transplantation, and subsequent maintenance are distinct stages. Successful collection does not mean high-dose therapy has been completed or that further medicines are unnecessary. If different hospitals or countries will provide these stages, the clinical teams should coordinate timing, prior drug exposure, storage, and any transfer requirements.
Transplant ineligibility does not mean there is no strong treatment option
Several antibody-based combinations have been studied in newly diagnosed people unable to undergo transplantation. MAIA compared daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone, showing disease-control and survival benefits while requiring attention to infection and cytopenias. It supports one option without establishing superiority over every other modern regimen. MAIA overall-survival analysis
IMROZ examined the addition of isatuximab to bortezomib, lenalidomide, and dexamethasone. Trial populations differ in age limits, function, and eligibility, so response percentages from separate studies should not be arranged as a universal ranking. The clinician should explain which evidence best matches the person, especially when marked frailty or several organ problems are present. IMROZ randomized trial
In January 2026, the FDA approved subcutaneous daratumumab and hyaluronidase with VRd for newly diagnosed adults ineligible for autologous transplantation. Its announcement explicitly distinguishes ineligibility from simply refusing initial transplantation. Chinese indications and institutional access need separate confirmation. An overseas approval headline cannot replace assessment of its applicability to an individual. FDA 2026 newly diagnosed myeloma approval
Renal impairment can change the immediate priorities
When the myeloma is harming the kidneys, reducing the harmful light-chain burden promptly is an important objective. Hematology and renal teams may need to work together. Bortezomib-based treatment has a major role in this setting, but the complete regimen, doses, and monitoring must still be individualized. Dialysis or reduced renal function does not automatically exclude every useful anticancer therapy. IMWG renal impairment recommendations
Some drugs require renal dose adjustment, and supportive medicines and contrast examinations also need consideration. Tell the team about pain medicines, blood-pressure treatment, supplements, and nonprescription products. Do not respond to kidney concerns by drinking excessive fluid or using a purported detoxification remedy. Fluid management depends on cardiac status, urine output, and electrolytes.
Early review should consider both protein or light-chain response and kidney function and overall condition. Kidney recovery may lag behind tumor-marker improvement, and dialysis or other support can remain necessary. Ask whether the current issue is delayed organ recovery or insufficient disease control so the plan is understood accurately.
Plan prevention alongside the first cycle
Infection susceptibility arises from the disease and its treatment. Review previous infections and vaccination history and obtain the preventive medicines appropriate to the proposed regimen. Patients do not all need the same antimicrobial program, and absence of fever is not a reason to stop prescribed prevention. Obtain a practical contact route for fever and a place for urgent local assessment. IMWG infection-prevention consensus
Certain immunomodulatory-drug and steroid combinations increase thrombotic risk. Prevention should reflect prior thrombosis, activity, other medicines, platelets, and bleeding risk. Do not independently copy another patient's aspirin or anticoagulant prescription. A newly swollen painful leg, sudden chest pain, or breathlessness should be assessed promptly rather than treated as an expected routine reaction.
Bone-directed medicines and assessment of pain and fracture risk also deserve early discussion. Kidney function, calcium, dental health, and plans for eventual discontinuation influence the choice and use of bisphosphonates or denosumab. Calcium and vitamin D supplementation should be appropriate to the actual situation rather than started without review in someone with unresolved hypercalcemia or renal problems. IMWG bone-disease treatment recommendations
Make the first-cycle feedback route explicit
The calendar should distinguish clinic treatment, oral medicines, steroid days, and planned breaks. Match brand names to generic names and record the actual prescription instead of copying a usual dose from an internet regimen. A relative may help check completion, but a missed dose or vomiting should be handled according to team instructions rather than by doubling the next dose.
Report new or worsening numbness, pain, postural dizziness, sleeplessness, mood change, glucose problems, rash, or troublesome bowel symptoms. Record the timing and impact on function. Early reporting gives the clinician an opportunity to address a problem before accumulated toxicity makes further therapy more difficult.
Chest tightness, wheezing, extensive rash, or altered awareness should not be saved for a later routine appointment. During administration, tell the staff immediately. After leaving, use the emergency instructions supplied by the team. International patients particularly need an out-of-hours care route rather than only a daytime booking number.
Agree on how and when response will be judged
Baseline protein, light-chain, blood-count, renal, and imaging information provides the comparison point. Follow-up should specify the relevant measurements and who will interpret them. Less pain is encouraging but cannot independently replace disease assessment. Structural bone damage can also persist despite benefit, so its continued visibility does not alone establish treatment failure.
An apparently limited response needs context: the assessment may be early, information incomplete, doses interrupted by toxicity, or the disease genuinely resistant. The next step may be continued observation of the trend, dose adjustment, another investigation, or a different regimen. Do not stop medicines after one disappointing result to seek an unverified promise of faster response elsewhere.
If transplantation is planned, response review should connect to collection and admission. Ask whether the conditions for the next stage have been met and which risks still require attention. This makes the tests part of a decision process rather than a growing collection of numbers without a clear purpose.
Starting in China requires a plan for what follows
China's 2025 national guidance on new anticancer medicines describes relevant myeloma medicines and use considerations. Formulations and combinations can have different scopes, including for daratumumab. The receiving team should check the current applicable documents rather than describe every overseas-approved combination as automatically available in China. National Health Commission guidance release
If induction will take place in China and subsequent care at home, confirm that the continuing medicines and toxicity monitoring can be obtained there. Supply interruption can disrupt the strategy, so verification should extend beyond the first cycle. A separate collection or transplant center should also be involved early enough to accept the handover.
An estimate in renminbi should identify the induction period, medicines, administration, tests, and supportive care, with collection, transplantation, and maintenance listed separately. A total supplied before clinical assessment cannot reliably represent an individual's entire course. Ask which events would change the estimate, such as an extended admission, altered dosing, or infection management.
Before starting, try to explain the purpose, next review point, and symptom contact route in your own words. If it is still unclear which medicine is taken daily and which only on designated days, ask the team to check the calendar with you. A clear start reduces preventable medication errors and establishes a practical foundation for longer-term myeloma care.